ResMed Inc. (NYSE: RMD) shares recently closed at USD 270.85, reflecting a daily change of -2.88 or -1.05%. This update examines the company’s current market status, financial indicators, and corporate profile for stakeholders monitoring healthcare sector performance.
In this article:
- Company Overview
- Stock Performance
- Market Position and Sector
- Governance and Leadership
- Key Financial Data
- FAQ
- Conclusion
- Disclaimer
- Official Source
Company Overview
ResMed Inc., headquartered in San Diego, California, is a healthcare company specializing in medical devices and cloud-based software solutions. Founded in 1989, the company operates globally with a presence in approximately 140 countries. Their product portfolio spans sleep and respiratory care devices, therapeutic masks, ventilation equipment, accessories, and software solutions targeted at improving patient outcomes. ResMed’s innovations include AirView, myAir, U-Sleep, Brightree, MatrixCare, and HEALTHCAREfirst, serving hospitals, sleep clinics, home health providers, and senior care organizations.
With a workforce of 9,980 full-time employees, ResMed addresses pressing healthcare challenges through integrated hardware and software solutions.
Stock Performance
On the latest trading day, ResMed shares settled at USD 270.85, down 2.88 from the previous session. The change percentage stood at -1.05%. This price is within the yearly range of USD 199.92 to USD 293.81, indicating the volatility and peaks experienced over the past 52 weeks.
Trading volume reached 1,314,465 shares, surpassing the average daily volume of 981,477 shares. Higher-than-average volume often signals increased investor interest or reaction to market news. The market capitalization currently stands at USD 39.65 billion, reflecting the company’s scale and valuation in the global healthcare market. The last declared dividend was USD 2.19 per share, relevant for income-focused investors assessing yield opportunities.
Market Position and Sector
ResMed operates in the “Medical – Instruments & Supplies” industry under the broader Healthcare sector. This positioning brings exposure to defensive market characteristics, often resilient against economic cycles due to ongoing demand for medical care. Competitors in this space range from large diversified healthcare equipment manufacturers to highly specialized firms.
ResMed’s market share benefits from its technological integration, leveraging cloud-based software to complement hardware offerings. This differentiator underscores their adaptability to telehealth and remote patient monitoring trends.
Governance and Leadership
The company is led by CEO Michael J. Farrell BE, MBA, SM. Under his leadership, ResMed has prioritized product innovation, international expansion, and digital health integration. Governance practices align with NYSE-listed company requirements, supported by reporting obligations and regulatory oversight to ensure transparency with stakeholders.
Key Financial Data
Trading Details
- Exchange: New York Stock Exchange (NYSE)
- ISIN: US7611521078
- CUSIP: 761152107
- CIK: 0000943819
- Currency: USD
- IPO Date: 1995-06-02
- Country of Headquarters: United States
- City: San Diego, California
- Address: 9001 Spectrum Center Boulevard, San Diego, CA 92123
- Phone: 858 836 5000
The combination of a mature listing history since 1995 and continued active trading illustrates the company’s established nature in public markets.
Key Indicators
- Share Price: USD 270.85
- 52-Week Range: USD 199.92 – USD 293.81
- Market Cap: USD 39.65 billion
- Dividend (last): USD 2.19
- Volume: 1,314,465 shares
- Average Volume: 981,477 shares
For investors, these figures support assessment of liquidity, market valuation, and income expectations.
FAQ
- What is ResMed’s latest dividend? The last dividend declared was USD 2.19.
- Where is ResMed listed? ResMed is listed on the New York Stock Exchange under the ticker RMD.
- How many employees does ResMed have? The company has 9,980 full-time employees.
- What is the ISIN code? ResMed’s ISIN is US7611521078.
- Who is the CEO? Michael J. Farrell BE, MBA, SM serves as the CEO.
Conclusion
ResMed Inc. presents a blend of stable healthcare demand and innovation-driven expansion through its integrated product and software portfolio. The latest stock movement reflects market sentiment that can shift with industry developments, earnings reports, or broader economic factors. Investors should consider the company’s scale, dividend history, and technological strengths when evaluating potential positions.
Disclaimer
This article is for informational purposes only and does not constitute financial advice. Investors should conduct independent research before making investment decisions.
Official Source
For full information about the company, see the link below.